Oncology · Medical Literature
Population Pharmacokinetics and Exposure-Response Analyses of Vepdegestrant, a First-in-Class PROteolysis-TArgeting Chimera Estrogen Receptor Degrader.
Abstract
Population pharmacokinetic (PK) and exposure-response analyses were performed to characterize the PK and exposure-response relationships of vepdegestrant, a first-in-class, oral PROteolysis-TArgeting Chimera estrogen receptor degrader. Population PK and exposure-response analyses for safety utilized data from the first-in-human study (ARV-471-mBC-101, NCT04072952) and the registrational VERITAC-2 study (NCT05654623), which included patients with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Safety endpoints of clinical interest were evaluated using logistic regression and included grade ≥3 treatment-emergent adverse events (TEAEs) and TEAEs of any grade (arthralgia, fatigue, nausea, aspartate aminotransferase or alanine aminotransferase elevations, anemia, and neutrophil count decreased). Exposure-efficacy analysis included patients with estrogen receptor-1 (ESR1)-mutated, ER-positive, HER2-negative advanced breast cancer from the VERITAC-2 vepdegestrant arm only. Progression-free survival (PFS) as assessed by blinded independent central review, the primary efficacy endpoint in VERITAC-2, was assessed via Cox proportional hazards modeling. Vepdegestrant PK was described by a two-compartment model with linear elimination and sequential zero-, first-order absorption. None of the evaluated covariates significantly influenced the disposition of vepdegestrant. There was no statistically significant relationship between vepdegestrant exposure and any of the evaluated safety endpoints across 30-500 mg total daily doses. In patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treated with vepdegestrant 200 mg once daily in the VERITAC-2 study, exposure was not a statistically significant predictor of PFS. Overall, integrated analyses adequately characterized the PK of vepdegestrant, with no clinically meaningful covariate effects. No exposure-response relationships were identified between vepdegestrant exposure and efficacy or safety outcomes.
Clinical relevance
In patients with ER-positive, HER2-negative advanced breast cancer (including those with ESR1 mutations), does vepdegestrant exposure (derived from a population pharmacokinetic model pooling the phase 1/2 ARV-471-mBC-101 study and the phase 3 VERITAC-2 registrational trial) correlate with progression-free survival and clinically relevant treatment-emergent adverse event rates, thereby supporting the adequacy of the approved 200 mg once-daily dose? __SNAPSHOT__ {"studyDesign":"Population pharmacokinetic (popPK) modeling with exposure-response analyses for safety (logistic regression) and efficacy (Cox proportional hazards); secondary pharmacometric analysis pooling data from two prospective clinical trials (phase 1/2 and phase 3)","setting":"Multicenter, global; data pooled from the first-in-human phase 1/2 study (ARV-471-mBC-101, NCT04072952) and the registrational phase 3 VERITAC-2 study (NCT05654623) conducted across 26 countries and 213 sites","sampleSize":"Safety exposure-response analyses: pooled patients from phase 1/2 and VERITAC-2 (exact n for popPK dataset not reported in the available abstract); efficacy exposure-response analysis restricted to the VERITAC-2 vepdegestrant arm in the ESR1-mutated subpopulation (n=136 in the ESR1-mutated vepdegestrant arm per VERITAC-2 primary analysis). Overall VERITAC-2 enrollment: n=624 (vepdegestrant n=313, fulvestrant n=311).","population":"Adults with ER-positive, HER2-negative advanced or metastatic breast cancer; safety analyses included patients from phase 1/2 and VERITAC-2; efficacy exposure-response analysis restricted to patients with confirmed ESR1-mutated disease from the VERITAC-2 vepdegestrant arm. VERITAC-2 required prior CDK4/6 inhibitor plus endocrine therapy (1 prior line) and up to one additional line of endocrine therapy. Randomization was stratified by ESR1-mutation status and presence of visceral disease.","intervention":"Vepdegestrant (ARV-471; brand name Veppanu), a first-in-class oral PROTAC ER degrader, administered at 200 mg once daily (the recommended phase 3 dose). PopPK model was used to generate individual exposure metrics (e.g., AUC, Cmax, Cthrough) used as predictors in exposure-response models.","comparator":"For the safety exposure-response analysis: within-arm analysis using individual model-derived exposure estimates vs. adverse event occurrence (logistic regression; no placebo or active comparator arm used in the pharmacometric model). For the efficacy exposure-response analysis: single-arm (vepdegestrant-only arm of VERITAC-2 in the ESR1-mutated subpopulation); not applicable as a head-to-head E-R analysis.","primaryOutcome":"Safety: probability of grade ≥3 treatment-emergent adverse events (TEAEs) and any-grade TEAEs of clinical interest (arthralgia, fatigue, nausea, AST/ALT elevations, anemia, and decreased neutrophil count), modeled via logistic regression against vepdegestrant exposure. Efficacy: progression-free survival (PFS) by blinded independent central review (BICR) in ESR1-mutated patients, assessed via Cox proportional hazards model against individual exposure metrics.","followUp":"Not reported in the available abstract; the parent VERITAC-2 trial had a median follow-up of approximately 7.4 months in the vepdegestrant arm at the time of the PFS analysis","fundingSource":"Industry (Pfizer and Arvinas; vepdegestrant is co-developed by Arvinas Operations, Inc. and Pfizer Inc.)"}
Key findings
Specific quantitative outputs of the popPK model (e.g., population estimates of clearance, volume of distribution, inter-individual variability) and the numerical results of the exposure-response regression models (odds ratios, hazard ratios by exposure quartile, p-values for the exposure-response relationships) are not available from the abstract alone and are therefore not reported here. Context from the parent VERITAC-2 trial (Campone et al., NEJM 2025) is provided to frame the clinical relevance: In the ESR1-mutated population (n=270), median PFS was 5.0 months (95% CI, 3.7–7.4) with vepdegestrant versus 2.1 months (95% CI, 1.9–3.5) with fulvestrant (HR 0.57; 95% CI, 0.42–0.77; p<0.001), representing a 43% relative reduction in the risk of disease progression or death. In the overall ITT population (n=624), median PFS was 3.8 months versus 3.6 months (HR 0.83; 95% CI, 0.69–1.01; p=0.07), which did not reach statistical significance. ORR in the ESR1-mutated subgroup was 19% (95% CI, 12–27%) with vepdegestrant versus 4% (95% CI, 1.6–10%) with fulvestrant. OS was immature at the time of the PFS analysis, with only 16% of deaths recorded in the ESR1-mutated population. Common any-grade TEAEs (≥10%) with vepdegestrant in VERITAC-2 included fatigue (27%), increased ALT (14%), increased AST (14%), nausea (13%), anemia (12%), and neutropenia (12%). Grade ≥3 TEAEs occurred in 23% of vepdegestrant-treated patients versus 18% with fulvestrant. Treatment discontinuation due to TEAEs was 3% in the vepdegestrant arm versus 1% in the fulvestrant arm. NNT for prevention of one PFS event in the ESR1-mutated population relative to fulvestrant: not calculable from reported medians alone; HR-based NNT is not reported. The present pharmacometric paper (PMID 42572241) characterizes these safety and efficacy signals through the lens of drug exposure, using individual model-predicted exposures as continuous predictors, but the specific slope estimates, odds ratios, and hazard ratios from those models are not available in the abstract.
Practice implications
This paper applies popPK and exposure-response methodology to data from two prospective trials to characterize whether vepdegestrant's PK exposure is a meaningful predictor of both efficacy (PFS in ESR1-mutated disease) and safety (specific TEAEs). The clinical importance of this work lies in supporting dose selection and regulatory justification for the approved 200 mg once-daily dose. The parent VERITAC-2 trial established that vepdegestrant significantly improves PFS versus fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer post-CDK4/6 inhibitor—the first positive phase 3 trial for any PROTAC therapy. FDA approved vepdegestrant (Veppanu) on May 1, 2026, restricted to the ESR1-mutated population as detected by an FDA-authorized companion diagnostic (Guardant360 CDx). The present pharmacometric analysis addresses an important gap: whether exposure variability within the approved dose drives differential safety or efficacy outcomes, which informs whether dose individualization or modification guidance is warranted. However, because only the abstract is available, the conclusions of the exposure-response models—including whether statistically significant exposure-efficacy or exposure-safety relationships were detected, and their direction and magnitude—cannot be confirmed or cited. Patients not represented in the efficacy analysis include those without ESR1 mutations (no PFS benefit in ITT), patients with ECOG PS >1, heavily pre-treated patients beyond two prior endocrine lines, and populations with hepatic or renal impairment (per standard trial exclusions). OS data remain immature. This analysis should be interpreted as a regulatory pharmacometric report supporting dose confirmation, not as an independent efficacy or safety trial. __LIMITATIONS__ Only the abstract is available for this specific pharmacometric paper (PMID 42572241); specific model parameters, exposure-response estimates, statistical outputs, and covariate findings cannot be independently reviewed or cited.,Population PK modeling pools data across phase 1/2 and phase 3 trials with different sampling schedules and patient populations, introducing potential structural model misspecification or bias if disease progression or prior treatment substantially alters PK.,Exposure-efficacy analysis is restricted to a single arm (vepdegestrant-only in the ESR1-mutated subpopulation), precluding determination of whether exposure differences explain outcomes at the individual level versus population level; without a concurrent control, exposure-response for PFS may be confounded by disease heterogeneity.,ESR1-mutated population represents only 43% (n=270) of the overall VERITAC-2 cohort, limiting generalizability of efficacy findings to unselected ER-positive, HER2-negative patients.,OS data were immature at PFS analysis cutoff (only 16% deaths in the ESR1-mutated population), so the long-term survival benefit of dose-optimized vepdegestrant is not established.,PFS is a time-to-event surrogate endpoint; the relationship between vepdegestrant exposure and OS is not reported.,The study is industry-sponsored (Pfizer/Arvinas), with potential for selective reporting bias, though this is a pharmacometric regulatory submission and not a hypothesis-generating trial.,The analysis is conducted at a single approved dose level (200 mg QD), severely limiting the exposure range and thus the sensitivity of exposure-response analyses to detect true dose-response relationships.,Logistic regression for safety events may be underpowered for rare grade ≥3 events (e.g., hepatotoxicity, neutropenia) if event counts are low.,Generalizability is limited to patients meeting VERITAC-2 eligibility criteria; patients with significant comorbidities, non-Western demographics, or extreme body habitus may not be adequately represented. __BOTTOM_LINE_CATEGORY__ practice_changing __BOTTOM_LINE__ Vepdegestrant (Veppanu) 200 mg once daily is the first FDA-approved PROTAC therapy, indicated for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer post-CDK4/6 inhibitor and endocrine therapy, based on a statistically significant and clinically meaningful improvement in PFS over fulvestrant (median 5.0 vs. 2.1 months; HR 0.57; p<0.001) in the ESR1-mutated subpopulation. This pharmacometric analysis (Yang, Masters, Wang et al., J Clin Pharmacol, 2026) provides the regulatory supporting evidence characterizing the PK-exposure-response relationships for both safety and efficacy, underpinning the adequacy of the approved dose, though detailed model outputs are not accessible from the abstract alone. Clinicians should confirm ESR1 mutation status using an FDA-authorized companion diagnostic (Guardant360 CDx) prior to prescribing, monitor for QTc prolongation and transaminase elevations, and counsel patients on embryo-fetal toxicity; no dose adjustments based on exposure-response findings are implied beyond published prescribing information at this time.